Transgender hormone therapy (male-to-female) orchiectomy still experience morning erections. Voluntary erections may or may not be possible, depending on the amount of hormones and/or antiandrogens being taken. Managing long-term hormonal regimens have not been studied and are difficult to estimate because research on the long-term use of hormonal therapy has not been noted. However, it is possible to speculate the outcomes of these therapies on transgender people based on the knowledge of the current effects of gonadal hormones on sexual functioning in cisgender men and women. Firstly, if one is to decrease testosterone in male-to-female gender transition, it is likely that sexual desire and
Biology and sexual orientation male sexual orientation. The research consisted of 1,077 homosexual men and 1,231 heterosexual men. A gene named SLITRK6 on chromosome 13 was identified, and contains an area or DNA sequence which is different for gay men than for heterosexual men. The research supports another study which had been done by Simon levay. Levay's research suggested that the hypothalamus of gay men is different from straight men. The SLITRK6 is active in the mid-brain where the hypothalamus is. The researchers found another gene, named "thyroid stimulating hormone receptor" (TSHR) on chromosome 14 which dna sequence is different also for gay men.